US7871984B2ExpiredUtilityA1
Methylated CpG polynucleotide
Assignee: TAISHO PHARMACEUTICAL CO LTDPriority: Apr 23, 2003Filed: Apr 23, 2004Granted: Jan 18, 2011
Est. expiryApr 23, 2023(expired)· nominal 20-yr term from priority
A61P 43/00A61P 7/04A61P 37/02A61P 37/06A61P 7/06A61P 3/10A61P 37/08A61P 9/10A61P 25/00A61P 31/00A61P 31/04A61P 29/00A61P 25/28C12N 2310/336C07H 21/02C07H 21/04A61P 1/04A61P 19/02A61P 11/02A61P 21/04A61P 17/16C12N 15/117A61P 17/00A61P 11/06
65
PatentIndex Score
2
Cited by
37
References
4
Claims
Abstract
It is an object of the present invention to provide a polynucleotide, which can effectively suppress the immunoreactivity caused by DNA having a CpG motif and which can be used for preventing and/or treating immune-mediated diseases such as arthritis. The present invention provides a polynucleotide comprising a CpG motif wherein guanine is methylated, and a pharmaceutical composition comprising the above-mentioned polynucleotide.
Claims
exact text as granted — not AI-modified1. A polynucleotide comprising a CpG motif wherein guanine of the CpG motif is methylated and the methylated guanine is 6-O-methyl-2′-deoxyguanosine which comprises the nucleotide sequence shown in any one of SEQ ID NOS: 1 to 4.
2. The polynucleotide comprising a CpG motif wherein guanine of the CpG motif is methylated and the methylated guanine is 6-O-methyl-2′-deoxyguanosine which consists of the nucleotide sequence shown in any one of SEQ ID NOS: 1 to 4.
3. A pharmaceutical composition which comprises the polynucleotide of claim 1 as an active ingredient and at least one pharmaceutically acceptable excipient.
4. A pharmaceutical composition which comprises the polynucleotide of claim 2 as an active ingredient and at least one pharmaceutically acceptable excipient.Join the waitlist — get patent alerts
Track US7871984B2 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.